Notably, combining therapies showed enhanced efficacy in blocking the invasiveness of CLL cells, highlighting a potential benefit of combined therapy of zilovertamab with BTK inhibitors for patients with CLL. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.